Background In this study, the frequency of human platelet antigen (HPA) alleles and genotypes of platelet donors in Wuhan was evaluated and differences in HPA distribution between Wuhan and other regions in China were compared.
Study Design and Methods: HPA genotyping was performed using RT-qPCR in 1516 platelet donors in Wuhan. The allele frequencies of HPA-1 to −6, −10, −15, and −21 were calculated and evaluated according to the Hardy-Weinberg principle. Mismatch probability was calculated for each HPA system. The distribution and features of HPA systems in Wuhan were compared to those of other regions in China.
Results The observed allele frequencies and expected frequencies of HPA-1 to −6, −10, −15, and −21 showed no significant differences according to the Hardy-Weinberg principle (all P > 0.05). The prevalent allele among the nine HPA systems assessed in this study was allele “a”, except in the HPA-3 and HPA-15, where allele “b” was found in 43.3 % and 46.9 % of platelet donors, respectively. The highest transfusion mismatch probability was found in HPA-15 (37.40 %) and HPA-3 (37.05 %). Compared to other regions of China, Wuhan exhibits distinct characteristics in the distribution of HPA allele frequencies and genotypes among platelet donors.
Conclusion Distinct gene frequencies and genotypes were observed for HPA-1 to −6, −10, −15, and −21 among 1516 platelet donors from Wuhan compared with those of other regions. These results highlight the fact that HPA genotyping is of great significance for the establishment of HPA genotype registry and precise platelet transfusion in Wuhan.
Funding
This work was supported by a grant from the Medical Research Project of Wuhan Municipal Health Commission (grant number WX19Q02) and a grant from the Natural Scientific Funding Project of Hubei Province (grant number 2024AFB986).
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgements
We thank the Natural Scientific Funding of Hubei Province and Wuhan Municipal Health Commission for their fundings to support the study.
Author contributions
Z.Q., G.S., and A.B. conceptualized and designed the study; Z.Q., W.L. and Y.Z. performed the experiments and data collection; Z.Q., M.H., and A.B. analyzed the data; Z.Q. and Y.Z. drafted the manuscript; G.S. and A.B. critically reviewed the manuscript.
| [1] |
S. Hamada, D. Garrigue, H. Nougue, et al., Impact of platelet transfusion on outcomes in trauma patients, Crit. care (Lond., Engl. ) 26 (1) (2022) 49.
|
| [2] |
J. Mandel, M. Casari, M. Stepanyan, et al., Beyond hemostasis: platelet innate immune interactions and thromboinflammation, Int. J. Mol. Sci. 23 (7) (2022).
|
| [3] |
F. Cognasse, A. Duchez, E. Audoux, et al., Platelets as key factors in inflammation: focus on CD40L/CD40, Front. Immunol. 13 (2022) 825892.
|
| [4] |
B. Chen, R. Xia, Pro-inflammatory effects after platelet transfusion: a review, Vox Sang. 115 (5) (2020) 349-357.
|
| [5] |
S. Lazar, L. Goldfinger, Platelets and extracellular vesicles and their cross talk with cancer, Blood 137 (23) (2021) 3192-3200.
|
| [6] |
L. Suping, L. Zefang, W. Suying, et al., The dynamic role of platelets in cancer progression and their therapeutic implications, Nat. Rev. Cancer 24 (1) (2023).
|
| [7] |
Y. Wen, D. Chen, Human platelet antigens in disease, Clin. Chim. Acta; Int. J. Clin. Chem. 484 (2018) 87-90.
|
| [8] |
B.R. Curtis, J.G. McFarland, Human platelet antigens - 2013, Vox Sang. 106 (2) (2014) 93-102.
|
| [9] |
J. Wang, X. Zhang, Y. Li, Prevention of platelet transfusion refractoriness by platelet antigen gene matching: a systematic review and meta-analysis, Ann. Palliat. Med. 10 (10) (2021) 10946-10953.
|
| [10] |
H. Inoue, R. Sakamoto, H. Nishimiya, et al., Minor impact of patient alloantibodies against human platelet antigen (HPA)-15 in the effectiveness of platelet transfusion: a pilot study, Transfusion 61 (3) (2021) 738-743.
|
| [11] |
K. Vu, A.D. Leavitt, Posttransfusion purpura with antibodies against human platelet antigen-4a following checkpoint inhibitor therapy: a case report and review of the literature[J], Transfusion 58 (10) (2018) 2265-2269.
|
| [12] |
T.W. de Vos, L. Porcelijn, S. Hofstede-van Egmond, et al., Clinical characteristics of human platelet antigen (HPA)-1a and HPA-5b alloimmunised pregnancies and the association between platelet HPA-5b antibodies and symptomatic fetal neonatal alloimmune thrombocytopenia[J], Br. J. Haematol. 195 ( 4) (2021) 595-603.
|
| [13] |
M. Hopkins, J. Brookes, D. Watson, et al., The first reported case of neonatal alloimmune thrombocytopenia due to low-frequency human platelet antigen-6b antibodies in the United Kingdom[J], Transfusion 61 (9) (2021) 2788-2794.
|
| [14] |
S. Davey, C. Navarrete, C. Brown, Simultaneous human platelet antigen genotyping and detection of novel single nucleotide polymorphisms by targeted next- generation sequencing[J], Transfusion 57 (6) (2017) 1497-1504.
|
| [15] |
M. Feng, D. Liu, W. Shen, et al., Establishment of an HPA-1- to -16-typed platelet donor registry in China, Transfus. Med. (Oxf., Engl. ) 16 (5) (2006) 369-374.
|
| [16] |
J. Juskewitch, A. Norgan, S. De Goey, et al., How do I … manage the platelet transfusion-refractory patient ?. Transfusion 57 (12) (2017) 2828-2835.
|
| [17] |
A. Schmidt, T. Sahai, M. Refaai, et al., Severe Platelet Transfusion Refractoriness in Association with Antibodies Against CD36, Lab. Med. 51 (5) (2020) 540-544.
|
| [18] |
M. Matsuhashi, N. Tsuno, S. Sone, et al., The role of alloantibodies against human platelet antigen-15 in multiply platelet transfused patients, Transfusion 54 (4) (2014) 1093-1099.
|
| [19] |
N. Medolago, A. Ferrasi, O. Rocha, et al., Human platelet antigen-3 polymorphism as a risk factor for rheumatological manifestations in hepatitis C, Rev. da Soc. Bras. De. Med. Trop. 53 (2020) e20190210.
|
| [20] |
S. Jovanovic Srzentic, M. Lilic, N. Vavic, et al., Genotyping of eight human platelet antigen systems in serbian blood donors: foundation for platelet apheresis registry, Transfus. Med. hemotherapy: Off. Organ der Dtsch. Ges. fur Transfus. und Immunhamatol. 48 (4) (2021) 228-233.
|
| [21] |
W.X. Che Jin, Jingmin Ma, Feng Li, Yanhua Feng, Analysis on the blood donor platelet HPA gene polymorphism in the Beijing Han population, Chin. J. Blood Transfus. 31 (4) (2018) 5.
|
| [22] |
Y.F. Han Yu, Lingling Liu, Jianghong Yu, Xiaofei Men, Jingying Zhang, Lixin Jiao, Mei Qiu, Analysis of gene polymorphism of human platelet antigen of the Han population in Jilin province, Chin. J. Lab Diagn. 26 (1) (2022) 4.
|
| [23] |
L.L. Yu Mei,Li Hengcong, Lu Fang, Pei Yongfeng, Huang Huini, Wu Guoguang, The design and establishment of the platelet donor database with known HLA / HPA genotype in Nanning area, Chin. J. Blood Transfus. 31 (11) (2018) 6.
|
| [24] |
Z.Y. Cao Jianping, Deng Yongle, Cheng Chao, Xie Jue, Polymorphism distribution of human platelet antigen gene HPA-1-6, 15 in Zhejiang Province, J. Clin. Hematol. (China). 31 (10) (2018) 4.
|
| [25] |
Yx Chen Yangkai, wenjie Xia, xiuzhang Xu, ling Deng, yuan Shao, haoqiang Ding, yongshui Fu, guangping Luo, Genetic polymorphism of HPA-1 to-17 al-loantigen system in Guangzhou population, Chin. J. Immunol. 26 (8) (2010) 4.
|
| [26] |
W.J. Li Mengdan, Ning Song, Youpan Xin, Xiaojuan Li, Dhondup Tashi, Zhong Liu, Qiang Chen, The polymorphism of HPA-1-6, -15 in Tibetan blood donors from Lhasa, Chin. J. Blood Transfus. 26 (6) (2013) 4.
|
PDF
(646KB)
